Reuters logo
BRIEF-Acura pharma up 12.4 percent premarket; says FDA to review data from failed painkiller trial
December 9, 2013 / 1:05 PM / 4 years ago

BRIEF-Acura pharma up 12.4 percent premarket; says FDA to review data from failed painkiller trial

NEW YORK, Dec 9 (Reuters) - Acura Pharmaceuticals Inc : * Pharma up 12.4 percent to $1.90 premarket; says FDA to review data from failed painkiller trial

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below